Neurology faculty and staff take leadership roles in national neuroscience clinical trials network
Neurology Department Chair and network PI, Dr. Mark Goldberg, was recently selected to serve on the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Executive Committee, while Mariam Andersen, M.A, CCRC, was elected Executive Coordinator for the network.
NeuroNEXT is a NINDS-funded initiative that provided infrastructure grant funds in 2011to 25 clinical sites around the United States. The NeuroNEXT Executive Committee is made up of NINDS representatives; Central Coordinating Center and Data Coordinating Center PIs; two elected PIs; and PIs from the highest enrolling site for each of the three studies that have completed enrollment periods to date.
Andersen was selected by project managers from the 25 NeuroNEXT sites. She will serve on the NeuroNEXT Executive Committee (NEC) for two years as the liaison between NEC and the other project managers. She will also provide feedback on submitted proposals, and join committee discussions.
UT Southwestern was the highest enrolling site for the NN103 “BEAT MG” study, led by Dr. Sharon Nations and research coordinator Steve Hopkins. Their enrollment numbers earned Dr. Mark Goldberg a place on the NeuroNEXT Executive Committee. BEAT MG is a placebo-controlled trial evaluating the safety, tolerability, and activity of rituximab administered in two 4-week infusion cycles in Myasthenia Gravis.
